Cannabis Law Report

JULY 18, 2022

Government minister Lord Kamall swerves this completely and diverts to a discussion on necessity for clinical trials, blaming the industry for not funding them. Debate starts with Baroness Meacher asking a question about GP prescribing.

Clinical Trials 52

Clinical Trials Medicine Cannabis Compliance 52

TheAnswerPage

MAY 23, 2022

Currently, clinical trials are evaluating CBD’s analgesic, neuroprotective, antiepileptic, anxiolytic, antipsychotic, anti-inflammatory, antitumor and anti-hypoxia/ischemia properties. The range of conditions for which CBD has been (or is being) assessed is quite diverse.

Clinical Trials 59

Clinical Trials Conditions CBD 59

Cannabis Law Report

JUNE 2, 2021

Researchers studying the efficacy of marijuana treatments for veterans’ mental health now have access to $20 million in marijuana tax revenue to fund clinical trials. None of it was initially slated to go to clinical trials. The deadline for proposals is Friday, July 16. Department of Veteran Affairs’ most recent data.

Clinical Trials 105

Clinical Trials Marijuana Recreational Collective 105

TheAnswerPage

MARCH 29, 2022

Has the National Institute of Drug Abuse (NIDA) recently provided funding for a clinical trial evaluating the efficacy of a CBD product as an opioid-sparing agent for patients with radiculopathic pain? Safety and tolerability of CBD will also be assessed throughout the trial. See the Answer.

Clinical Trials 52

Clinical Trials Safety Medicine Treatment 52

TheAnswerPage

JUNE 29, 2022

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

TheAnswerPage

FEBRUARY 8, 2022

No, not according to a 2020 clinical trial which involved the abrupt withdrawal of CBD after four-weeks of use (750 mg twice daily taken orally). Abrupt withdrawal of cannabidiol (CBD): a randomized trial. Do individuals who abruptly stop taking CBD experience physical withdrawal symptoms? Crockett, J., Checketts, D.,

Clinical Trials 59

Clinical Trials Epilepsy CBD 59

TheAnswerPage

JANUARY 9, 2022

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

Cannabis Law Report

MAY 31, 2022

The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. 2022 Active FDA Clinical Trials and State-Regulated Systems. Active FDA Regulated Clinical Trials*. On March 5, 2019, the U.S.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

TheAnswerPage

MAY 25, 2022

The results of recent clinical trials indicate that Cannabidiol (CBD) reduces seizures among patients with refractory epilepsies of various etiologies. Most of these clinical studies report efficacy over short time periods (.

Clinical Trials 52

Clinical Trials Epilepsy Treatment CBD 52

Cannabis Law Report

JULY 25, 2022

million ($650,000) in funding from New Zealand’s Health Research Council (HRC) to conduct a LSD microdosing trial in patients with Major Depressive Disorder (MDD). The state agency grant funding followed the successful completion of a phase 1 clinical trial in 80 healthy participants.

Microdosing 52

Microdosing Clinical Trials Research and Development Data 52

Cannabis Law Report

DECEMBER 21, 2021

Within a few months, it had completed the first phase of its clinical trial of DMT in combination with supportive psychotherapy and commenced a phase 2a trial. It’s also initiating phase 2a clinical trial into conditions such as eating disorders and fibromyalgia. 10 Psychedelic Companies To Watch In 2022.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). What are the common adverse events noted in clinical trials examining the efficacy of cannabinoids for ASD?

Clinical Trials 52

Clinical Trials Events Therapy Sleep 52

Cannabis Law Report

JULY 13, 2022

VANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. ( Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi’s strategic goals.”.

Therapy 52

Therapy Clinical Trials Microdosing Research and Development 52

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

MAY 19, 2022

This is Numinus’ first psilocybin-assisted therapy treatment outside of ongoing clinical trials, and among the first to use of this regulatory mechanism through Health Canada’s Special Access Program (“SAP”), which was amended January 5 th , 2022 to include access to psychedelic compounds on a case-by-case basis.

Therapy 52

Therapy Treatment Clinical Trials Access 52

Cannabis Law Report

NOVEMBER 1, 2021

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 135, 2022 (Forthcoming) , Available at SSRN: [link] or [link]. This Essay analyzes the ethical, legal, and social implications of patenting these controversial substances. Harvard Law Review Forum, Vol.

Research and Development 52

Research and Development Law Clinical Trials Therapy 52

Cannabis Law Report

FEBRUARY 9, 2022

Cybin plans to submit a clinical trial application for a pilot study of CYB004 in the second quarter of calendar year 2022 and expects to initiate the pilot study in the third quarter of calendar year 2022.

Treatment 52

Treatment Clinical Trials Research and Development 52

Veriheal

MARCH 20, 2023

Smith cited results from clinical trials showing that MDMA holds promise in the treatment of PTSD. Oklahoma In March 2022, Oklahoma state representatives presented a bill that, if approved, would allow clinical trials on psychedelics “in relation to depression, anxiety, opioid use disorder, and dementia.”

Clinical Trials 98

Clinical Trials Therapy Decriminalization Treatment 98

Cannabis Law Report

JULY 28, 2021

This includes First Time in Human (“FTiH”) clinical trials, which are expected to commence in 2022, for the Group’s lead compound OCT461201, a selective cannabinoid receptor type 2 (“CB2”) agonist with initial indications in the areas of post herpetic neuralgia and visceral pain caused by irritable bowel syndrome.

Cannabinoids 105

Cannabinoids Clinical Trials Safety Medicine 105

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. June 14, 2022 02:00 AM Eastern Daylight Time. However, we need rigorous clinical trials to ensure that this promise is realised.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Veriheal

FEBRUARY 9, 2023

A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. Although many rely on imaging scans to diagnose illnesses and get treatment of various kinds, getting into the enclosed chamber can be stressful. What Is an MRI?

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Cannabis Law Report

JANUARY 6, 2022

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that management will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Business 52

Cannabis Law Report

FEBRUARY 24, 2022

Each request is decided on a patient-by-patient basis and approval is usually only given to drugs with successful phase II or phase II clinical trials. The 2013 amendment cut off access to SAP for psychedelic drugs like MDMA and psilocybin, leaving clinical trials as the only vehicle for patients to access psychedelic services.

Therapy 52

Therapy Access Clinical Trials Treatment 52

Cannabis Law Report

AUGUST 17, 2021

Orphan drug designation provides certain benefits, including market exclusivity upon regulatory approval, if received, exemption of FDA application fees and tax credits for qualified clinical trials. Conference Call and Webcast Details. Marinus will host a conference call and webcast with slides at 4:30 p.m.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

AUGUST 10, 2022

9, 2022 /CNW/ – MediPharm Labs Corp. The lead investigators are Jacobo Mintzer , MD, MBA, Brigid Reynolds , ANP-BC, and the Alzheimer’s Clinical Trial Consortium (ACTC).The ” Study Details – provided by Alzheimer’s Clinical Trial Consortium. BARRIE, ON , Aug. MediPharm Labs Corp.

Clinical Trials 52

Clinical Trials Medicine Pharmaceutical THC 52

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. April 5, 2022.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

FEBRUARY 9, 2022

If approved by shareholders, the demerger gives Reset the opportunity to solely focus on developing is psychedelics business, and will become its own unlisted entity during the June 2022 quarter. “We

Clinical Trials 52

Clinical Trials Research and Development Medicine Business 52

Cannabis Law Report

SEPTEMBER 22, 2021

Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023. Exclusive licensing agreement with leading global cannabis company (“Canopy Growth”).

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

DECEMBER 9, 2021

(the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has completed the manufacturing of its clinical grade supply (“cGMP”) of AP-188 (“ N , N -Dimethyltryptamine or DMT”) at Canadian manufacturer Dalton Pharma Services.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 24, 2022

DUBLIN–(BUSINESS WIRE)–The “North America Legal Cannabis Market Size, Share & Trends Analysis Report by Sources (Marijuana, Hemp), by Derivatives (CBD, THC), by End Use (Medical, Recreational), and Segment Forecasts, 2022-2028” report has been added to ResearchAndMarkets.com’s offering. from 2022 to 2028.

Legalization 52

Legalization Supply Chain Chronic Pain Recreational 52

Cannabis Law Report

JANUARY 11, 2022

UPDATED : Wednesday 12th of January 2022. The new distributor in the Australian medicinal cannabis industry – The Entourage Effect – has signed a firstof its kind deal with innovative medical cannabis clinic MiDispensary. Legal cannabis partnership to help patient access. SYDNEY, AUSTRALIA –.

Access 52

Access Patients Clinical Trials Legalization 52

Cannabis Law Report

JUNE 17, 2021

Jazz said it expects to generate 65% of 2022 revenues from products that have been launched or acquired since 2019. As part of our continued R&D efforts we also look forward to advancing our PTSD and essential tremor programs, the nabiximols clinical trial program to support a U.S. net leverage by the end of 2022.

Pharmaceutical 108

Pharmaceutical Clinical Trials Therapy Programs 108

Cannabis Law Report

APRIL 2, 2022

Bienstar Plans To Build LATAM’s First Network of Integrative Mental Health Clinics. TORONTO, ON / ACCESSWIRE / March 31, 2022 / Novamind Inc. a leader in specialized ibogaine treatments for substance use disorder based in Sao Paolo, Brazil (the “Ibogaine Group”).

Clinical Trials 52

Clinical Trials Research and Development Medicine Therapy 52

Cannabis Law Report

JUNE 9, 2022

Draft Law of Ukraine “On Amendments to Certain Legislative Acts of Ukraine Concerning the Regulation of the Circulation of Cannabis Plants for Medical, Industrial Purposes, Scientific and Scientific-Technical Activities” February 17, 2022. Draft Law of Ukraine. ARV (revised). REFERENCE to the EU acquis. explanatory note.

Seed-To-Sale 52

Seed-To-Sale Legalization Cultivation Medicine 52

Cannabis Law Report

MARCH 18, 2022

March 18, 2022. Food and Drug Administration (FDA) guidance on clinical trials, Drug Enforcement Agency (DEA) licensing, material transfer agreements and cooperative research and development agreements (CRDA). By Steve Levine & Marshall Custer.

Therapy 52

Therapy Research and Development Clinical Trials Environment 52

Cannabis Law Report

JANUARY 12, 2022

11, 2022 (GLOBE NEWSWIRE) — Gb Sciences, Inc. “We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.” LAS VEGAS, Jan. “This is a landmark event for Gb Sciences,” said Chairman and CEO John Poss.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

JANUARY 19, 2022

January 17, 2022. – January 17, 2022) – Psygen Industries Ltd. received a dealer’s licence issued by Health Canada on January 17, 2022 (the “ Dealer’s Licence “). received a dealer’s licence issued by Health Canada on January 17, 2022 (the “ Dealer’s Licence “).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Conditions 52